Key facts
- This page summarizes Neil S. Belloff's Form 4 filing for Eloxx Pharmaceuticals, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Jul 2021, 20:32.
Neil S. Belloff - 30 Jul 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.
- Reporting relationship
- COO, GENERAL COUNSEL &CORP SEC
- Issuer ticker
- ELOX on Nasdaq
- Reported as of
- 30 Jul 2021
- Net transaction value
- -$606
- SEC form
- 4
- Accepted by SEC
- 30 Jul 2021, 20:32:44 UTC
- Prior SEC filing
- 26 May 2021
- Next SEC filing
- 09 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Neil S. Belloff
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil S. Belloff filed Form 4 for Eloxx Pharmaceuticals, Inc. on 30 Jul 2021.
Change
- Previous filing in this sequence was filed on 26 May 2021.
- Current net transaction value: -$606.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELOX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,563
- Change %
- +4.9%
- Price
- $0.000000
- Shares after
- 33,158
- Date
- 30 Jul 2021
- Ownership
- Direct
- Footnotes
- F1
ELOX
transaction
Common Stock
Tax liability
- Transaction value
- $606
- Shares
- -459
- Change %
- -1.4%
- Price
- $1.32
- Shares after
- 32,699
- Date
- 30 Jul 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELOX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,563
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 9,375
- Date
- 30 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,563
- Exercise price
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
Footnote F4
The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction.